BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, June 6, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 9, 2020
View Archived Issues
Nuvation conducts phase I/II study of NUV-422 in recurrent or refractory high-grade gliomas
Read More
Celyad begins phase I trial of CYAD-211 for relapsed or refractory multiple myeloma
Read More
Jacobio initiates first-in-human study of JAB-8263 in advanced solid tumors
Read More
Natural killer cells kill aging cognition
Read More
Enrollment open in phase Ib/II study of KRT-232 with acalabrutinib in DLBCL and CLL
Read More
ION-251 enters first-in-human trial for relapsed or refractory multiple myeloma
Read More
Positive data presented from global MOMENTUM trial of SRP-5051
Read More
Topline data from phase III DARE-BVFREE study of DARE-BV1 in women with bacterial vaginosis
Read More
Relmada initiates phase III program for REL-1017 as adjunctive therapy in MDD
Read More
FDA issues complete response letter for Furoscix
Read More
QLB Biotherapeutics describes bispecific anti-CD3 and CD20 antibodies
Read More
ACSS2 inhibitors discovered at Metabomed
Read More
UCB patents antimalarials
Read More
New GBA2 inhibitors disclosed by Alectos Therapeutics
Read More
Teligene identifies new protein kinase inhibitors
Read More
"Transomics" show altered glucose metabolism in obesity
Read More
Lyra Therapeutics presents positive data from phase II LANTERN study of LYR-210
Read More
Phase I/II data support further study of CAR T-cell therapy MB-CART2019.1 in B-cell NHL
Read More
FDA allows IND for phase I/II trial of Artiva's NK cell therapy AB-101 for NHL
Read More
FDA clears IND for first-in-human study of KB-0742 for MYC-amplified tumors
Read More
Vicore reports topline data on use of C-21 for COVID-19
Read More
Axsome reports phase II data on AXS-05 in patients with MDD with suicidal ideation
Read More
QRA-244 could counteract disease progression due to hyperexcitability in patients with ALS
Read More
Ysopia begins phase I trial of Xla-1 for obesity and metabolic disorders
Read More
FDA accepts IND for phase Ib study of CERC-007 for relapsed or refractory multiple myeloma
Read More
